Primary Myelofibrosis (PMF)
A chronic bone marrow disorder in which progressive scarring (fibrosis) disrupts normal blood cell production, often driven by JAK2, CALR, or MPL gene mutations.
- JAK2/CALR/MPL mutation testing
- IPSS/DIPSS risk stratification
- JAK inhibitor therapy
- Allogeneic transplant evaluation
- Most Common In
- Adults over 60
- Driver Mutations
- JAK2, CALR, MPL
- Key Feature
- Bone marrow fibrosis
- Curative Option
- Allogeneic stem cell transplant
- Advanced Therapies
- JAK inhibitors, clinical trials
Condition Overview
Primary myelofibrosis is a rare, chronic myeloproliferative neoplasm in which the bone marrow gradually replaces healthy blood-forming tissue with fibrous scar tissue. This disrupts normal production of red cells, white cells, and platelets, often causing the spleen and liver to take over some blood-forming function, leading to enlargement of these organs.
Types and Classification
PMF is classified by disease stage and by the underlying driver mutation, both of which influence prognosis and treatment selection.
Symptoms and Signs
Symptoms develop gradually and reflect both impaired blood cell production and an enlarging spleen.
Causes and Risk Factors
PMF results from acquired genetic mutations in blood stem cells that drive abnormal proliferation and bone marrow scarring. Most cases are not inherited.
Diagnosis and Investigations
Diagnosis combines blood testing, bone marrow examination, and molecular profiling to confirm PMF and distinguish it from related disorders.
Risk Stratification
PMF prognosis is estimated using clinical risk scoring systems such as the IPSS, DIPSS, or DIPSS-Plus, which incorporate age, blood counts, symptoms, and genetic findings.
Standard Treatment
Treatment is individualized based on risk category, symptom burden, and transplant eligibility, ranging from observation to JAK inhibitor therapy to transplantation.
Advanced & Emerging Therapies
Newer agents and clinical trial options are expanding choices beyond standard JAK inhibitor therapy, particularly for patients with persistent cytopenias or treatment-resistant disease.
Targeted Therapy
Next-generation JAK inhibitors
Newer JAK inhibitors aim to improve anemia management alongside spleen and symptom control.
Combination Therapy
JAK inhibitor combination regimens
Combining JAK inhibitors with other targeted agents is being studied to deepen and prolong response.
Cellular Therapy
Allogeneic stem cell transplant
Remains the only potentially curative option, with access to international transplant centers explored for eligible patients.
Novel Agents
BET inhibitors and telomerase inhibitors
Investigational agents being studied for patients with refractory or progressive disease.
Biomarkers & Precision Medicine
Molecular testing guides diagnosis, risk stratification, and selection of targeted therapy.
When to Seek a Second Opinion
Given the complexity of risk stratification and treatment timing in PMF, a second opinion can help clarify the optimal path forward.
Clinical Trials & Research
Prognosis & Outcomes
Prognosis in PMF varies considerably depending on risk category, mutation profile, and response to treatment, with risk scoring tools used to guide individualized expectations.
Supportive Care
Supportive measures help manage symptoms and complications alongside disease-directed treatment.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients with primary myelofibrosis review their mutation profile and risk score, connect with MPN specialists, and explore JAK inhibitor or transplant options, including access to centers internationally.
Get a free case reviewFrequently Asked Questions
Primary myelofibrosis is a chronic bone marrow disorder in which scar tissue gradually replaces normal blood-forming tissue, impairing the production of red cells, white cells, and platelets.
Early signs often include fatigue, unintentional weight loss, night sweats, and abdominal fullness from an enlarging spleen, though some patients are diagnosed incidentally through routine blood tests.
It is caused by acquired mutations, most commonly in the JAK2, CALR, or MPL genes, that drive abnormal blood stem cell proliferation and bone marrow scarring.
Diagnosis involves blood tests, a bone marrow biopsy to assess fibrosis grade, and molecular testing for JAK2, CALR, and MPL mutations.
Allogeneic stem cell transplant offers the only potentially curative option, though it is not suitable for all patients. Other treatments aim to control symptoms and manage disease progression.
These are the three main driver mutations in PMF. CALR-mutant disease is generally associated with a more favorable course, while triple-negative disease (none of the three) tends to carry a less favorable prognosis.
A subset of patients with PMF can progress to acute myeloid leukemia over time, which is one reason for ongoing monitoring of blood counts and blast percentages.
JAK inhibitors are used to reduce spleen size and relieve constitutional symptoms in patients with intermediate- or high-risk disease.
Risk scoring systems such as IPSS, DIPSS, and DIPSS-Plus combine age, blood counts, symptoms, and genetic findings to estimate prognosis and guide treatment timing.
Yes. CancerFax helps review medical reports and mutation panels, coordinates second opinions with MPN specialists, and supports access to JAK inhibitor therapy, clinical trials, and transplant programs, including China-based and international centers.
Get Expert Guidance on Your Myelofibrosis Diagnosis
Share your reports and mutation testing results to explore treatment options, second opinions, and access to specialist centers.